Merck signals beyond the news: 56+ signals from 6 sources
The latest Merck signal on this page is from Oct 27, 2026 (Patents): "Merck Sharp & Dohme's patent output is steady: 1 grant in the past year, 0 in the past 30 days." The busiest sources: Glassdoor (15+), Website changes (15+) and X (Twitter) (12).
Get Merck's live signals in Claude or ChatGPT, or by API
What changed at Merck this week? Use Autobound signals for merck.com.- Signals
- 56+
- Sources
- 6
- Last 90 days
- 41
- Latest
- Oct 27, 2026
Source: Autobound Signal API · 92 signals tracked for Merck · updated
Other signals · latest 10
Latest Merck signals by source
56+ signals for Merck across 6 sources.
Patents · Patent pace
Merck Sharp & Dohme's patent output is steady: 1 grant in the past year, 0 in the past 30 days.
Over the past year Merck Sharp & Dohme received 1 US patent grant; the recent pace (1 in 90 days) is steady versus its trailing baseline.
- Grants, 12 months
- 1
- Grants, 90 days
- 1
- Grants, 30 days
- 0
- USPTO assignee
- Merck Sharp & Dohme
Reddit · Customer feedback
A chemist working with sensitive compounds complains that commercial functionalized silica gels from suppliers like Merck are insanely expensive and is seeking protocols to synthesize them in-house.
Post: "NH Functionalized silica gel"
- Subreddit
- r/Chempros
- Upvotes
- 3
- Comments
- 14
- Sentiment
- Negative
X (Twitter)
Merck is presenting new oncology data, including three Phase 3 trials, at the ESMO Congress.
We’re presenting new data from our industry-leading #oncology pipeline and portfolio at this year’s ESMO Congress, including three presentations from pivotal Phase 3 trials in Presidential Symposia. Learn more about our commitment to advancing research across a range of cancer types: https://t.co/2xeshcwz2X
- Account
- @Merck
- Views
- 2,503
- Likes
- 21
- Reposts
- 3
X (Twitter)
Merck is presenting Phase 2b/3 trial data for a diabetic macular edema drug at AAO2026.
Today at #AAO2026, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME). Learn more: https://t.co/OQ0Fv8F5nc https://t.co/G7fdiPoI1L
- Account
- @Merck
- Views
- 1,831
- Likes
- 11
- Reposts
- 3
Glassdoor · Consistent leadership complaints
Senior executives and maintenance technicians cite confusing and ineffective management
A Senior Maintenance Technician describes managers as having 'no clue what is really going on', while a Senior Executive mentions difficulty managing working hours, suggesting potential management issues.
- Overall rating
- 4.1 of 5
- CEO approval
- 83%
- Reviews read
- 10
- Review window
- Oct 4, 2026 to Oct 9, 2026
Glassdoor · Poor work life balance
Burnout and long working hours cited by multiple employees
A Senior Clinical Database Analyst reported burnout from poorly managed departments, and a Senior Executive mentioned difficulty managing working hours.
- Overall rating
- 4.1 of 5
- CEO approval
- 83%
- Reviews read
- 10
- Review window
- Oct 4, 2026 to Oct 9, 2026
Reddit · Customer feedback
A Reddit user describes Merck's interview process as the 'slowest and worst', noting that it frequently results in a rejection for the candidate.
Post: "Which company has you thinking this?"
- Subreddit
- r/biotech
- Upvotes
- 846
- Comments
- 68
- Sentiment
- Negative
Patents · Patent grant
Merck Sharp & Dohme was granted a patent for nitrosamine testing.
In September 2026 Merck Sharp & Dohme patented a rapid quality-control method for detecting trace nitrosamines in solid pharmaceutical samples.
- Patent title
- Method for analyzing trace levels of semi-volatile nitrosamines in solid samples
- Grant date
- Sep 8, 2026
- Inventors
- Rebecca Evans, Xinxin Han, Daniel E. Lee, Christine L. Radich
Website changes · Customer win
Merck highlighted key regulatory and clinical milestones across its broad, diverse pipeline.
Added news release: “Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline.”
- Page
- /media
Podcasts · Customer experience focus
One Day in Transformation discusses Merck: customer experience focus
"They're looking at their business and saying, what patients are we leaving behind and why? and really making sure that they're understanding that and studying that and doing things about it."
- Podcast
- One Day in Transformation
- Episode
- Celeste Warren: Why Equity Is a Business Imperative, Not a Trend
- Speaker
- Celeste Warren
- Speaker role
- Third party
Showing 10 of 56+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Merck with the Signal API
One POST /v1/companies/enrich call with merck.com returns Merck signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "merck.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Other signals at related companies
Questions about Merck other signals
What signals does Autobound track for Merck besides news and filings?
What are people saying about Merck online?
What do employees say about working at Merck?
Has Merck been granted patents recently?
Page updated , the date of the newest row on this page.
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .